Preservation Request – QoVAX COVID-19 Vaccine Biospecimens

Metro North CEO, Adjunct Professor Jackie Hanson

MD16-MetroNorthHHS@health.qld.gov.au

The Chair, Metro North HREC

MetroNorthResearch-Ethics@health.qld.gov.au

The Honourable David Crisafulli MP

thepremier@premiers.qld.gov.au

Preservation Request – QoVAX COVID-19 Vaccine Biospecimens

We are writing to you on behalf of the organization NORTH Group, working to raise awareness and instigate action in relation to the actual and potential harms resulting from mRNA products – and in particular the COVID-19 genetic vaccines.

NORTH Group was initiated on 25th November 2024, when an international group of doctors, nurses, scientists, lawyers as well as elected representatives from countries around the world wrote to the heads of state of 10 European countries citing serious health concerns regarding COVID-19 modified mRNA vaccines. The initiative is now supported in 25 countries by over 1400 international signatories. For more information, please see our website (northgroup.info).

NORTH Group is deeply concerned about the plans to dispose of critical research material held within the QoVAX Study biobank in Queensland, Australia.

Our organization plays a crucial role in advocating for COVID-19 vaccine safety and transparency, with a main aim of restoring the regulatory process and in the regulatory authorities' ability to ensure the highest standards of drug safety and quality without compromising public health, thereby restoring public trust.

Having worked closely with colleagues in Australia including Russell Broadbent in his former capacity of Member of Parliament, and Julian Gillespie, we call for transparency from regulatory agencies and governments in respect of excessive residual DNA contamination within the COVID-19 mRNA vaccines.

’Raising awareness about the potential harms posed by modified mRNA products’ 1 NORTHGroup.info

15th July 2025

We therefore wish to highlight the critical nature of maintaining the QoVAX Study biobank for future forensic and scientific analyses related to the residual DNA contamination phenomenon.

The biobanked samples provide a unique opportunity to quantify the amount of residual DNA in individuals as well as the potential for genomic integration. The QoVAX samples would enable the dose of residual DNA contamination to be correlated with subsequent health conditions and to identify and validate methods to quantify the pathological sequalae of synthetic DNA exposure. Since two of the most likely pathological outcomes of DNA exposure are rapidly progressing /(’turbo’) cancer and a marked reduction in fertility, the biobank provides a unique opportunity to help understand these catastrophic outcomes and to reverse the damage caused by the COVID-19 vaccines.

We wish to iterate in no uncertain terms that the QoVAX resource must be preserved for the scientific community, indeed the world community, particularly those that have been and continue to suffer from COVID-19 vaccine injuries. It would be a humanitarian travesty on no uncertain terms if this resource is disposed of. We stand ready to assist Metro North seek a solution for the preservation of this globally significant resource.

Your attention to this matter is greatly appreciated.

Yours sincerely,

Dr. Jonathan Gilthorpe

Dr. Jeanne Rungby

NORTH Group

contactus@northgroup.info